Humacyte to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference at Nasdaq
Humacyte (NASDAQ: HUMA), a commercial-stage biotechnology company focused on developing universally implantable, bioengineered human tissues, has announced its participation in the H.C. Wainwright 3rd Annual BioConnect Investor Conference. The event will take place at the Nasdaq World Headquarters in New York on May 20, 2025.
The company's Founder, President, and CEO, Laura Niklason, M.D., Ph.D., will participate in a fireside chat at 12:30 p.m. EST. Management will also be available for one-on-one meetings. A webcast replay will be accessible through the Events & Presentations section of Humacyte's website.
Humacyte (NASDAQ: HUMA), un'azienda biotecnologica in fase commerciale specializzata nello sviluppo di tessuti umani bioingegnerizzati e universalmente impiantabili, ha annunciato la sua partecipazione al H.C. Wainwright 3rd Annual BioConnect Investor Conference. L'evento si terrà presso la sede mondiale del Nasdaq a New York il 20 maggio 2025.
La Fondatrice, Presidente e CEO dell'azienda, Laura Niklason, M.D., Ph.D., parteciperà a una conversazione informale alle 12:30 EST. Il management sarà inoltre disponibile per incontri individuali. Una replica in webcast sarà disponibile nella sezione Eventi e Presentazioni del sito web di Humacyte.
Humacyte (NASDAQ: HUMA), una empresa biotecnológica en etapa comercial enfocada en desarrollar tejidos humanos bioingenierizados e implantables universalmente, ha anunciado su participación en la 3ª Conferencia Anual de Inversores BioConnect de H.C. Wainwright. El evento se realizará en la sede mundial de Nasdaq en Nueva York el 20 de mayo de 2025.
La fundadora, presidenta y CEO de la compañía, Laura Niklason, M.D., Ph.D., participará en una charla informal a las 12:30 p.m. EST. La dirección también estará disponible para reuniones individuales. Una repetición en webcast estará accesible a través de la sección Eventos y Presentaciones en el sitio web de Humacyte.
Humacyte (NASDAQ: HUMA)는 보편적으로 이식 가능한 생체공학 인간 조직 개발에 중점을 둔 상업 단계의 생명공학 회사로, H.C. Wainwright 제3회 연례 BioConnect 투자자 컨퍼런스에 참가한다고 발표했습니다. 이 행사는 2025년 5월 20일 뉴욕 나스닥 월드 본사에서 개최됩니다.
회사 창립자이자 사장 겸 CEO인 Laura Niklason, M.D., Ph.D.가 동부 표준시 오후 12시 30분에 파이어사이드 채팅에 참여할 예정입니다. 경영진은 일대일 미팅도 진행할 예정입니다. 웹캐스트 재생은 Humacyte 웹사이트의 이벤트 및 프레젠테이션 섹션에서 이용할 수 있습니다.
Humacyte (NASDAQ: HUMA), une entreprise biotechnologique en phase commerciale spécialisée dans le développement de tissus humains bio-ingénierés universellement implantables, a annoncé sa participation à la 3e conférence annuelle BioConnect pour investisseurs de H.C. Wainwright. L'événement se tiendra au siège mondial du Nasdaq à New York le 20 mai 2025.
La fondatrice, présidente et PDG de la société, Laura Niklason, M.D., Ph.D., participera à une discussion informelle à 12h30 EST. La direction sera également disponible pour des réunions individuelles. Une rediffusion en webcast sera accessible via la section Événements et Présentations du site web de Humacyte.
Humacyte (NASDAQ: HUMA), ein biotechnologisches Unternehmen in der kommerziellen Phase, das sich auf die Entwicklung universell implantierbarer, bioengineerter menschlicher Gewebe spezialisiert hat, hat seine Teilnahme an der 3. jährlichen BioConnect Investorenkonferenz von H.C. Wainwright angekündigt. Die Veranstaltung findet am 20. Mai 2025 im Nasdaq World Headquarters in New York statt.
Die Gründerin, Präsidentin und CEO des Unternehmens, Laura Niklason, M.D., Ph.D., wird um 12:30 Uhr EST an einem Fireside Chat teilnehmen. Das Management steht auch für Einzelgespräche zur Verfügung. Eine Webcast-Wiedergabe wird im Bereich Veranstaltungen & Präsentationen auf der Humacyte-Website verfügbar sein.
- None.
- None.
DURHAM, N.C., May 19, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that Laura Niklason, M.D., Ph.D., Founder, President, and Chief Executive Officer, will present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference at Nasdaq in New York, NY on Tuesday, May 20, 2025. Management will also be available for one-on-one meetings.
Event: H.C. Wainwright 3rd Annual BioConnect Investor Conference at Nasdaq
Location: Nasdaq World Headquarters, New York, NY
Fireside Chat: Tuesday, May 20, 12:30 p.m. EST
Webcast: https://journey.ct.events/view/66adb5ff-a0d8-42aa-b1d2-70b2e6d726f1
A replay will be available for a limited time following the presentation on the Events & Presentations portion of the Humacyte website.
About Humacyte
Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues, advanced tissue constructs, and organ systems designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Humacyte’s Biologics License Application for the acellular tissue engineered vessel (ATEV) in the vascular trauma indication was approved by the FDA in December 2024. ATEVs are also currently in late-stage clinical trials targeting other vascular applications, including arteriovenous (AV) access for hemodialysis and peripheral artery disease (PAD). Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte’s 6mm ATEV for AV access in hemodialysis was the first product candidate to receive the FDA’s Regenerative Medicine Advanced Therapy (RMAT) designation and has also received FDA Fast Track designation. Humacyte’s 6mm ATEV for urgent arterial repair following extremity vascular trauma and for advanced PAD also have received RMAT designations. The ATEV received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense. For more information, visit www.Humacyte.com.
For uses other than the FDA approval in the extremity vascular trauma indication, the ATEV is an investigational product and has not been approved for sale by the FDA or any other regulatory agency.
Humacyte Investor Contact:
Joyce Allaire
LifeSci Advisors LLC
+1-617-435-6602
jallaire@lifesciadvisors.com
investors@humacyte.com
Humacyte Media Contact:
Rich Luchette
Precision Strategies
+1-202-845-3924
rich@precisionstrategies.com
media@humacyte.com
FAQ
When is Humacyte (HUMA) presenting at the H.C. Wainwright BioConnect Conference?
Who will be presenting for Humacyte at the H.C. Wainwright Conference?
Where can investors watch Humacyte's H.C. Wainwright Conference presentation?
What type of company is Humacyte (HUMA)?
